Dr Chong Chyn Chua

Learn more about Monash Health’s Haematology team.

Dr Chong Chyn Chua

MBBS BMedSc FRACP FRCPA PhD

Dr Chyn Chua is a clinical and laboratory haematologist with a strong focus in malignant haematology, specialising in Acute Myeloid Leukaemia (AML) and Myeloid Neoplasms. Her expertise is rooted in two years of dedicated fellowship training in AML/MDS at Alfred Health, and a PhD through the Australian Centre for Blood Diseases, Monash University, conducting translational research investigating novel therapeutic strategies in patients with AML.

Dr Chua’s mission is to improve outcomes for patients diagnosed with AML and MDS. She leads the AML initiatives at Monash Health and serves as a Principal Investigator on phase 1- 4 clinical trials in this area. Her passion for clinical and translational research is evident through her leadership in several Australasian investigator-initiated clinical trials via the Australasian Leukaemia and Lymphoma Group (ALLG). She chairs the ALLG AML frailty special interest group. She also holds academic roles as Research Fellow at Walter and Eliza Hall Institute of Medical Research, and an adjunct senior lecturer at Monash University. Her research has been published in high-impact journals including Journal of Clinical Oncology, Blood, and Blood Advances.

Key recent publications

Tiong IS, Hiwase DK, Abro E, Bajel A, Palfreyman E, Beligaswatte A, Reynolds J, Anstee N, Nguyen T, Loo S, Chua CC, Ashby M, Fleming S, Fong CY, The TC, Blombery P, Dillon R, Ivey A, Wei AH. A prospective phase 2 study in AML targeted measurable molecular residual disease and low-blast relapse with venetoclax and low dose cytarabine (VALDAC study). Accepted by Journal of Clinical Oncology Dec 2023

Moujalled D, Brown F, Chua CC, Dengler M, Pomilio G, Anstee N, Litalien V, Thompson E, Morley T, MacRaild S, Tiong I, Morris R, Dun K, Zordan A, Shah J, Banquet S, Halilovic E, Morris E, Herold M, Lessene G, Adams J, Huang D, Roberts A, Blombery P, Wei AH. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia. Blood. 2023 Feb. 141(6): 634-644. https://doi.org/10.1182/blood.2022016090

Chua CC, Cheok KPL. Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome. Lancet Haematology. 2023 Mar. 10(3):E161-162. https://doi.org/10.1016/S2352-3026(23)00002-9

Chua CC, Hammond D, Kent A, Tiong IS, Konopleva M, Pollyea DA, DiNardo CD, Wei AH. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Advances. 2022 May. 6(13):3879-3883. Doi: https://doi.org/10.1182/bloodadvances.2022007083

Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon J, MacRaild S, Ivey A, Tiong IS, Fleming S, Brown F, Loo S, Majewski IJ, Bohlander S, Wei AH. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase 1b dose escalation study of venetoclax combined with modified intensive chemotherapy. Journal of Clinical Oncology. 2020 38:30, 3506-3517. Doi: 10.1200/JCO.20.00572

Our Emergency Departments are experiencing extreme demand. If your condition is urgent but not a medical emergency, please consider alternative care options.Learn more
+